ArticleObesity science & practice2020
Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program.
Article in Obesity science & practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction.Diabetes, obesity & metabolism · 2026Review
- Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.Cureus · 2026Review
- Five-year Weight Loss Maintenance With Obesity Pharmacotherapy.The Journal of clinical endocrinology and metabolism · 2023Article
- Weight changes following antidiabetic mediation use: Real-world evidence from health system data.Obesity science & practice · 2022Article
- Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland.Obesity facts · 2021 · on this mapObservational
- Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program.Obesity science & practice · 2020Article
- Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada.Obesity science & practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWeight management medications can significantly increase patients' chances of achieving a clinically meaningful weight loss if patients persist with treatment. This retrospective observational study of de-identified medical records of 311 patients is the first real-world study examining persistence with liraglutide 3.0 mg in Canada, and also investigates associations between the SaxendaCare® patient support program and persistence and weight loss.
methodsOverall persistence was assessed, as well as associations of enrollment in SaxendaCare®, persistence and weight loss.
resultsOverall mean (standard deviation) persistence with liraglutide 3.0 mg was 6.3 (4.1) months, and 67.5% (
conclusionsThese findings suggest that, in clinical settings, persistence with liraglutide 3.0 mg can exceed 6 months, and that enrolling in SaxendaCare® may be associated with comparatively longer persistence and, regardless of persistence, greater weight loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.